Movers & Shakers - Spark Newswire

1 minute read

Belite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study

Today, 7:09 AM

Belite Bio (NASDAQ: BLTE) has initiated enrollment for the U.S. Phase 3 clinical trial of its lead asset LBS-008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment.

BLTE

1 minute read

Warren Buffett Not Expected to Bid for Control of Occidental Following Approval for Bigger Stake

By Charles Gross

Today, 7:09 AM

-Wall Street Journal https://www.wsj.com/articles/warren-buffett-not-expected-to-bid-for-control-of-occidental-following-stake-boost-11661099924

BRK-A

3 minute read

Unrivaled Brands & Other Cannabis Operators Just Made Some Key Executive Changes You Should Know About

By Jelena Martinovic

Today, 7:09 AM

As Benzinga Cannabis Capital Conference returns on September 13-14 to Chicago, gathering top CEOs, investors and leaders in the industry, let's scroll through the latest leadership changes within the space.</

IXHL

2 minute read

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate

By Ragothaman Srinivasan

Today, 7:09 AM

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.

AXSM

1 minute read

89bio Shares Climb After Concluding Enrolment In Mid-Stage NASH Study

By Ragothaman Srinivasan

Today, 7:09 AM

89bio (NASDAQ: ETNB) has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).

ETNB

1 minute read

RedHill Shares Gain As European Commission Grants Orphan Drug Status To NTM Infections Candidate

By Ragothaman Srinivasan

Today, 7:09 AM

The European Commission has granted Orphan Drug Designation to RedHill Biopharma’s (NASDAQ: RDHL) lead asset RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.

RDHL

1 minute read

Palisade Bio Shares Drop Following Commencement Of Late-Stage Return Of Bowel Study

By Ragothaman Srinivasan

Today, 7:09 AM

Palisade Bio (NASDAQ: PALI) has dosed first patient in its Phase 3 study evaluating lead asset LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.

PALI

3 minute read

Watch Out Tesla And Waymo! Lyft Debuts Self-Driving Vehicle In Las Vegas

By Dylan Wechsler

Today, 7:09 AM

Ride-hailing service Lyft Inc. (NASDAQ: LYFT) has teamed up with Motional to bring self-driving taxis to cities around the nation, starting with Las Vegas.

AUR

1 minute read

Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint

By Ragothaman Srinivasan

Today, 7:09 AM

Aptinyx Inc. (NASDAQ: APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. The Phase 2b clinical study was designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia.

APTX

2 minute read

WWE’s Vince McMahon Is Back In The Hot Seat: New SEC Filing Reveals More Information Amid Misconduct Investigation

By Dylan Wechsler

Today, 7:09 AM

Former World Wrestling Entertainment, Inc. (NYSE: WWE) CEO Vince McMahon is once again in the hot seat after a new U.S. Securities and Exchange Commission (SEC) regulatory filing.

WWE